Waiving IP for Covid-19 related health products and technologies: prospects and solutions

Date: 23 June 2021

The webinar assessed the current state of play and prospects for an intellectual property (IP) waiver in response to the Covid-19 pandemic. The panel assessed the proposal of India and South Africa for a TRIPS waiver, the announcement that the United States is prepared to support the waiving of IP for Covid-19 vaccines, and the counter proposal of the EU.

The event was jointly hosted by the Queen Mary Intellectual Property Research Institute (QMIPRI), Queen Mary University of London, and the Intellectual and Industrial Property Rights Research and Application Center (FISAUM), Ankara University.

Welcome

• Professor Dr Duncan Matthews - Director of the Queen Mary Intellectual Property Research Institute, Queen Mary University of London

Moderator

• Professor Dr Arzu Oğuz (Moderator) - Director of the Intellectual and Industrial Rights Research and Application Center (FISAUM), Ankara University

Panel

• Dr Burcu Kilic - Research Director, Access to Medicines Program, Public Citizen
• Dr Luke McDonagh - Assistant Professor of Law, London School of Economics and Political Science (LSE)
• Dr Dhanay Cadillo Chandler - Post-Doctoral Researcher, University of Turku and Visiting Professor, LUISS School of Law
• Professor Dr Duncan Matthews - Director of the Queen Mary Intellectual Property Research Institute, Queen Mary University of London